SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule | Telmisartan | Testosterone | Prednisone |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Angiotensin II receptor blocker medicine | Endogenous androgen / prescription androgen medicine | Systemic glucocorticoid prodrug medicine |
| PrimeCore Class | Class AApproved in a bounded context | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Telmisartan is classified here as Angiotensin II receptor blocker medicine. Controlled cardiovascular evidence and labels apply to hypertension and selected risk-reduction contexts. FDA-authorised prescription products exist for defined cardiovascular indications; supplier tablets require product-specific verification. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Testosterone is an endogenous androgen and an active ingredient in authorised prescription medicines, but 'Test' does not identify an ester, formulation, strength, manufacturer or authorisation. Cypionate, enanthate, undecanoate, propionate, no-ester formulations and blends are not automatically interchangeable. TRAVERSE found MACE noninferiority for a specific gel in a defined population while other safety signals remained. This evidence does not authenticate catalogue products or support performance use. WADA 2026 prohibits testosterone and its esters at all times. | Prednisone is classified here as Systemic glucocorticoid prodrug medicine. Extensive prescription evidence applies to disease-specific regimens and monitoring, not general recovery or performance use. FDA-authorised prescription products exist; WADA prohibits systemic glucocorticoids in competition by specified routes and requires current rule checking. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions
Telmisartan